Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/24/2025

Treatment of Acute Exacerbations of COPD and Asthma

Introduction to Treatment Guidelines

  • The British Thoracic Society recommends initiating treatment with bronchodilators such as salbutamol (2.5-5 mg) or terbutalina (5-10 mg) or ipratropio (500 μg) every 4-6 hours, and considering combination therapy (β-agonist 2.5-10 mg with ipratropio 250-500 μg) in more severe cases 1

Treatment of COPD

  • The British Thoracic Society suggests considering adding furosemide (40 mg) to conventional treatment if the patient presents with significant dyspnea or suboptimal response to initial bronchodilator treatment, although the evidence is limited and not included in current treatment guidelines 1

Treatment of Asthma

  • Furosemide (40 mg) may be considered as an adjunctive treatment in selected cases of asthma with short-duration exacerbations (<8 hours) and suboptimal response to standard treatment, but its use is not recommended as a standard treatment for asthma exacerbations due to limited evidence 2

Monitoring and Assessment

  • Patients should be monitored for FEV1 or PEF, dyspnea intensity, arterial blood gases (if available), and vital signs (blood pressure, heart rate, and respiratory rate) 1

Evidence and Recommendations

  • The evidence for nebulized furosemide in COPD and asthma is limited, with small studies and variable results, and it is not included in current treatment guidelines for COPD or asthma 2, 3
  • The benefit of furosemide appears to be greater in COPD exacerbations than in asthma, and in asthma, it may be limited to short-duration exacerbations 2